U.S. Reaches Major Milestone With Half of All States Requiring the Use of Technology to Combat the Opioid Crisis

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

State and Federal Laws Enacted to Drive Physician Use of Electronic Prescribing for Controlled Substances (EPCS)

ARLINGTON, Va.–(BUSINESS WIRE)–#EHR–The nation has reached a major milestone in its fight against the opioid epidemic, with more than half of all states requiring the use of electronic prescribing for opioids, controlled substances or all prescriptions.


On June 14, Texas Governor Greg Abbott signed H.B. 2174, followed by Florida Governor Ron DeSantis signing H.B. 831 on June 18, and Delaware Governor John Carney, Jr. signing H.B. 115 on June 27.

This means that the U.S. has passed the halfway point in its effort to enact requirements meant to spur adoption of Electronic Prescribing for Controlled Substances (EPCS), and arm prescribers with the technology they need to safely, securely and efficiently prescribe controlled substances, including opioids for pain management.

“We’ve worked across the Surescripts Network Alliance™ and with industry partners in states from coast to coast to ensure that this powerful technology realizes its full impact on patients and the people who care for them,” said Tom Skelton, Chief Executive Officer of Surescripts. “To combat the opioid crisis—one of the biggest issues in healthcare today—we must all work together to digitize prescriptions and arm care providers with the actionable intelligence they need to make optimal care decisions and deliver adequate pain management.”

State and federal legislators have increasingly recognized the value of EPCS because it replaces paper prescriptions and helps eliminate the risk of theft or forgery. When combined with electronic access to patient medication history data and other tools at the point of care, providers can identify potential misuse and enhance the accuracy, security, privacy and efficiency of the prescribing process.

As of 2018, 95% of pharmacies were enabled for EPCS, although prescriber enablement lagged behind at 32%. And while 85% of prescriptions for non-controlled substances were sent electronically last year, just 31% percent of controlled substance prescriptions were sent electronically (a 10% increase from 2017).

Prescribers in states where electronic prescribing is required by law have driven substantial growth in enablement and adoption of EPCS. In New York, the I-STOP law helped increase prescriber and pharmacy enablement of EPCS to 77% and 98% respectively. And in 2018, 85% of all controlled substances in the state were prescribed electronically, according to Surescripts 2018 National Progress Report.

At the federal level, the SUPPORT for Patients and Communities Act (H.R. 6), which Congress passed and President Trump signed into law in October 2018, requires the use of EPCS for all controlled substances under Medicare Part D by January 1, 2021.

Prescribers can visit www.GetEPCS.com to learn how to implement the technology.

About Surescripts

Our purpose is to serve the nation with the single most trusted and capable health information network, built to increase patient safety, lower costs and ensure quality care. Since 2001, Surescripts has led the movement to turn data into actionable intelligence and convened the Surescripts Network Alliance™ to enhance prescribing, inform care decisions and advance the healthcare industry. Visit us at surescripts.com and follow us at twitter.com/surescripts.

Contacts

Kelly Jeffers

Surescripts

(571) 384-4776

kelly.jeffers@surescripts.com

Staff

Recent Posts

FinThrive Introduces Agentic AI at HFMA 2025 to Help Customers Transform Healthcare Revenue Cycle Management Performance

Company to also highlight advancements in denials and underpayments management and speak to the measurable…

4 hours ago

FinThrive Debuts Denials and Underpayments Analyzer, a Unified Solution for Denials and Underpayments, at HFMA 2025

Next generation analyzer helps hospitals protect revenue before it's lost by delivering timely end-to-end visibility…

4 hours ago

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine

Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed mean weight reduction…

7 hours ago

Dr. Anosh Ahmed Advances Chicago Crypto Hub Project as Federal Support for Blockchain Grows

Dr. Anosh Ahmed repurposes West Side warehouse into blockchain innovation center, targeting 250+ jobs and…

7 hours ago

Dr. Anosh Ahmed Advances Chicago Crypto Hub Project Amid National Pro-Crypto Policy Shift

Dr. Anosh Ahmed converts vacant West Side warehouse into blockchain innovation hub, creating 250+ jobs…

7 hours ago

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits…

7 hours ago